SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced a collaboration with the University of California , Irvine to evaluate biomarkers detected
Leading clinical investigator to utilize Biocept's liquid biopsy tests for the detection of ALK rearrangements at baseline and to monitor treatment response and resistance mechanisms over time
SAN DIEGO , Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announced today that the Company's previously announced
SAN DIEGO , Dec. 22, 2015 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC) (" Biocept " or the "Company"), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection, monitoring and treatment of cancer, announces a $15 million common stock
SAN DIEGO --(BUSINESS WIRE)--Aug. 16, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 .
SAN DIEGO --(BUSINESS WIRE)--May 16, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022 .
Collaboration highlights the power and versatility of the proprietary Switch-Blocker technology, which may be applied to molecular diagnostics in COVID-19 and other infectious diseases, in addition to oncology applications currently commercialized and in development SAN DIEGO , Aug.
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC ), a leading commercial provider of liquid biopsy solutions, announces that it has entered into an agreement with Agiomix FZ-LLC ("Agiomix"), a provider of genomics sample and bioinformatics services to customers around the
Healthcare Group supports more than 50 skilled nursing facilities SAN DIEGO , Aug. 13, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve outcomes, announces it
Biocept's Target Selector™ to be used in profiling and monitoring patients diagnosed with non-small cell lung cancer throughout an integrated healthcare delivery system SAN DIEGO , Aug. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests
